Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
Waters L, Assoumou L, González-Cordón A, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masiá M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell JM, Pozniak A, Martínez E; NEAT 022 Study Group. Waters L, et al. Among authors: gompels m. Clin Infect Dis. 2023 Mar 4;76(5):861-870. doi: 10.1093/cid/ciac827. Clin Infect Dis. 2023. PMID: 36259527 Clinical Trial.
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.
Strategies for Management of Antiretroviral Therapy (SMART) Study Group; Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, et al. J Infect Dis. 2008 Apr 15;197(8):1133-44. doi: 10.1086/586713. J Infect Dis. 2008. PMID: 18476292 Clinical Trial.
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.
Strategies for Management of Antiretroviral Therapy (SMART) Study Group; Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, et al. J Infect Dis. 2008 Apr 15;197(8):1145-55. doi: 10.1086/529523. J Infect Dis. 2008. PMID: 18476293 Clinical Trial.
Virological response to initial antiretroviral regimens containing abacavir or tenofovir.
Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J, Dunn D, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M, Walsh J, Orkin C, Easterbrook P, Gompels M, Phillips A; UK Collaborative HIV Cohort Study. Bansi L, et al. Among authors: gompels m. J Infect Dis. 2009 Sep 1;200(5):710-4. doi: 10.1086/605024. J Infect Dis. 2009. PMID: 19635022
Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.
Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Rodger AJ, et al. J Infect Dis. 2009 Sep 15;200(6):973-83. doi: 10.1086/605447. J Infect Dis. 2009. PMID: 19678756 Free PMC article. Clinical Trial.
Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.
Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients; Lodwick RK, Sabin CA, Porter K, Ledergerber B, van Sighem A, Cozzi-Lepri A, Khaykin P, Mocroft A, Jacobson L, De Wit S, Obel N, Castagna A, Wasmuth JC, Gill J, Klein MB, Gange S, Riera M, Mussini C, Gutiérrez F, Touloumi G, Carrieri P, Guest JL, Brockmeyer NH, Phillips AN. Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients, et al. Lancet. 2010 Jul 31;376(9738):340-5. doi: 10.1016/S0140-6736(10)60932-4. Epub 2010 Jul 15. Lancet. 2010. PMID: 20638118 Free PMC article.
Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA; HIV-CAUSAL Collaboration. del Amo J, et al. Clin Infect Dis. 2012 May;54(9):1364-72. doi: 10.1093/cid/cis203. Epub 2012 Mar 28. Clin Infect Dis. 2012. PMID: 22460971 Free PMC article.
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe.
De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I, Kaiser R, Sönnerborg A, Codoñer FM, Van Laethem K, Vandamme AM, Bansi L, Ghisetti V, van de Vijver DA, Asboe D, Prosperi MC, Di Giambenedetto S; SEHERE collaboration in Chain. De Luca A, et al. J Infect Dis. 2013 Apr 15;207(8):1216-20. doi: 10.1093/infdis/jit017. Epub 2013 Jan 11. J Infect Dis. 2013. PMID: 23315324
233 results